Platelet 12-Lipoxygenase Activation via Glycoprotein VI: Involvement of Multiple Signaling Pathways in Agonist Control of H(P)ETE Synthesis
Marcus J. Coffey, Gavin E. Jarvis, Jonathan M. Gibbins, Barbara Coles, Natasha E. Barrett, Oliver R.E. Wylie and Valerie B. O'Donnell

_Circ Res._ 2004;94:1598-1605; originally published online May 13, 2004;
doi: 10.1161/01.RES.0000132281.78948.65
_Circulation Research_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/94/12/1598

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation Research_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation Research_ is online at:
http://circres.ahajournals.org/subscriptions/
Platelet 12-Lipoxygenase Activation via Glycoprotein VI
Involvement of Multiple Signaling Pathways in Agonist Control of H(P)ETE Synthesis

Marcus J. Coffey, Gavin E. Jarvis, Jonathan M. Gibbins, Barbara Coles, Natasha E. Barrett, Oliver R.E. Wylie, Valerie B. O'Donnell

Abstract—Lipoxygenases (LOX) contribute to vascular disease and inflammation through generation of bioactive lipids, including 12-hydro(pero)xyeicosatetraenoic acid (12-H(P)ETE). The physiological mechanisms that acutely control LOX product generation in mammalian cells are uncharacterized. Human platelets that contain a 12-LOX isoform (p12-LOX) were used to define pathways that activate H(P)ETE synthesis in the vasculature. Collagen and collagen-related peptide (CRP) (1 to 10 μg/mL) acutely induced platelet 12-H(P)ETE synthesis. This implicated the collagen receptor glycoprotein VI (GPVI), which signals via the immunoreceptor-based activatory motif (ITAM)-containing FcRγ chain. Conversely, thrombin only activated at high concentrations (> 0.2 U/mL), whereas U46619 and ADP alone were ineffective. Collagen or CRP-stimulated 12-H(P)ETE generation was inhibited by staurosporine, PP2, wortmannin, BAPTA/AM, EGTA, and L-655238, implicating src-tyrosine kinases, PI3-kinase, Ca²⁺ mobilization, and p12-LOX translocation. In contrast, protein kinase C (PKC) inhibition potentiated 12-H(P)ETE generation. Finally, activation of the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing platelet endothelial cell adhesion molecule (PECAM-1) inhibited p12-LOX product generation. This study characterizes a receptor-dependent pathway for 12-H(P)ETE synthesis via the collagen receptor GPVI, which is negatively regulated by PECAM-1 and PKC, and demonstrates a novel link between immune receptor signaling and lipid mediator generation in the vasculature. (Circ Res. 2004;94:1598-1605.)

Key Words: platelets lipoxygenase collagen collagen receptor glycoprotein VI

Lipoxygenases (LOX) catalyze lipid hydroperoxide formation from unsaturated fatty acids. Many LOX isoforms are found in the vasculature: some constitutive (eg, p12-LOX in platelets, 5-LOX in neutrophils), others cytokine-inducible (eg, 15-LOX by interleukin-4 (IL-4) in monocytes). Compelling evidence exists for critical involvement of LOXs in vascular and inflammatory diseases including atherosclerosis, cancer, hypertension, and diabetes.

Cellular LOXs require direct activation before product generation occurs. Typically, this requires (1) oxidation of the ferrous iron to an intermediate that abstracts hydrogen from unsaturated lipid and (2) translocation of the cytosolic enzyme to nuclear or plasma membrane. This activation is inhibited by membrane translocation inhibitors; and (3) 15-LOX turnover by addition of arachidonate substrate with/without Ca²⁺ ionophore. These studies implicate Ca²⁺-dependent translocation, serine and tyrosine phosphorylation, and LOX association with accessory proteins such as 5-lipoxygenase activating protein (FLAP), although their involvement in LOX activation using physiological agonists is not established. Acute activation of LOXs has been reported for neutrophil 5-LOX by fMLP and p12-LOX in platelets by collagen; however, the receptors involved and intracellular signaling pathways remain uncharacterized. Additionally, modulation of LOX activity within cells by agonist-mediated feedback mechanisms has not been examined.

This study utilized washed human platelets as a model to define receptor-dependent and intracellular mechanisms of LOX activation by acute physiological agonists. The data shows (1) collagen or collagen-related peptide (CRP) signal-
Platelet 12-Lipoxygenase Activation by GPVI

Coffey et al

Acid (EGTA), 1,2-bis(2-aminophenoxy)ethane-acetoxymethyl ester (BAPTA/AM), FURA-2/AM, A23187, PP2, p38-MAP kinase inhibitor (MKI), staurosporine, chelerythrine chloride, and bis-indolylmaleimide were from Calbiochem Ltd. All other reagents and reagents were from Sigma Ltd, unless otherwise stated.

Preparation of Washed Human Platelets
Platelets were isolated as described\(^{20}\) from consenting donors who were NSAID-free for 2 weeks before donating. Washed platelets were resuspended in Ca\(^{2+}\)-free Tyrode buffer (in mmol/L: 134 NaCl, 12 NaHCO\(_3\), 2.9 KCl, 0.34 NaH\(_2\)PO\(_4\), 1 MgCl\(_2\), 10 HEPES, 5 glucose, pH 7.4).

Acute Activation of Platelets With Agonists and Sample Preparation for HPLC

3×10\(^8\) platelets in 100 µL Tyrodes, 1 mmol/L CaCl\(_2\), were stimulated with either collagen (1 to 10 µg/mL), CRP (0.05 to 10 µg/mL) (synthesized to a published sequence\(^{18}\)), convulxin (1 µg/mL protein concentration) (a kind gift from Dr S.P. Watson, University of Oxford, UK), thrombin (0.04 to 2.0 U/mL), the calcium ionophore, A23187 (1 µmol/L), arachidonic acid (20 µmol/L), the thromboxane mimetic, U46619 (10 µmol/L), or ADP (5 µmol/L) at 37°C with agitation for 10 minutes. Experiments using signaling inhibitors included a 10-minute preincubation step at 37°C before addition of collagen or CRP (both 10 µg/mL). Incubations were stopped by the addition of 200 µL ice-cold methanol and samples spun at 10,000 g for 10 minutes at 4°C. Supernatants containing 12-H(P)ETE were recovered and supplemented with 200 ng 15(S)-HEDE per sample as an internal standard.

Reverse Phase HPLC Analysis of Platelet 12-LOX Products

Samples (equivalent to 2×10\(^7\) cells per sample run) were separated on a 150 mm×4.6 mm, 5 µm C\(_8\) ODS2 (Waters Ltd) column using 50% to 90% B over 20 minutes (A = water:acetonitrile:acetic acid, 75:25:0.1, B = methanol:acetonitrile:acetic acid, 60:40:0.1) at 1 mL/min. Absorbance was monitored at 235 nm. Products were identified and quantified using 200 ng 12(S)-HEDE standard run in parallel under the same conditions.

Optical Aggrecomegometry

Aggregation of 4×10\(^5\) washed platelets/mL in response to CRP (0.05 µg/mL) was measured in siliconized-glass cuvettes at 37°C with constant stirring in a PAP4 optical aggrecomegometer (Bio/Data Corp). Platelets were incubated with anti-PECAM-1 antibody (AB468, 1 µg/mL) for 5 minutes, followed by cross-linking for 90 seconds with F(ab\(^\prime\))\(_2\) fragments of anti-IgG secondary antibody (30 µg/mL). Mouse monoclonal IgG (1 µg/mL) plus F(ab\(^\prime\))\(_2\) fragments of anti-IgG secondary antibody (30 µg/mL) were utilized as isotype controls. CRP (0.05 µg/mL) was then added and aggregation responses measured.

FURA-2/AM Fluorescence

Washed platelets were incubated at 4×10\(^6\)/mL with 2.5 µmol/L FURA-2/AM for 45 minutes before washing at 800 g for 10 minutes. Fluorescence was measured after agonist addition, using a Perkin Elmer 50B fluorescence spectrophotometer at 37°C with stirring (ε\(_r\), 340 nm, 380 nm; ε\(_m\), 509 nm).

Statistical Analysis

Data are representative of at least 3 separate donors, with samples run in triplicate (Error bars are for mean±SEM). Significance was examined using an unpaired t test where P<0.05 was considered significant (denoted by * on figure). Activity in the presence of inhibitors is expressed % relative to the collagen or CRP response, as appropriate.

Results

Collagen and CRP Stimulate p12-LOX Product Generation in Washed Human Platelets

Incubation of platelets with collagen or CRP led to 12-H(P)ETE synthesis in a dose- and time-dependent manner (Figure 1). 12-H(P)ETE generation in response to agonists was confirmed by coelution with (1) authentic 12-H(P)ETE standard, and (2) 12-H(P)ETE generated after arachidonate activation of platelets. Furthermore, its synthesis was inhibited by LOX inhibitors baicalein or NDGA (Figure 2A). Peroxide analysis of platelet lysates determined that 12-H(P)ETE comprised predominantly 12-HETE, with 12-H(P)ETE content being 2.7±1.5% or 0.7±0.02% for collagen or CRP, respectively (not shown). Collagen treatment showed a lag-phase of approximately 25 seconds before a rapid linear increase over 2 minutes, followed by a slower phase of product generation from 2 to 10 minutes (Figure 1D). CRP showed a similar lag phase with product generation increasing linearly over 1 to 5 minutes (Figure 1F). Synthesis of 12-H(P)ETE did not require addition of exogenous fatty acid or Ca\(^{2+}\) ionophore, indicating that arachidonate substrate originated from internal phospholipid hydrolysis. A crude fraction of venom from Crotalus durissus terrificus containing convulxin, which selectively activates GPVI, also efficiently stimulated 12-H(P)ETE generation (Table).

Incubation of platelets with thrombin (<0.2 U/mL) failed to stimulate 12-H(P)ETE synthesis (Table). Nonphysiological concentrations of thrombin, up to 2.0 U/mL did stimulate, although far less than collagen or CRP (not shown). Finally, neither ADP nor the thromboxane A\(_2\) mimetic, U46619, activated p12-LOX when added alone (Table). This was in comparison to arachidonate or A23187 activated 12-H(P)ETE synthesis, as previously shown.\(^{14}\)

Ca\(^{2+}\) Mobilization Is Necessary but Not Sufficient for GPVI Stimulation of 12-H(P)ETE Synthesis

To examine whether Ca\(^{2+}\) mobilization is required or sufficient for GPVI-stimulated p12-LOX product generation, platelets were first activated in Ca\(^{2+}\)-free buffer with EGTA (1 mmol/L) to chelate extracellular Ca\(^{2+}\), with/without BAPTA/AM (10 µmol/L). With EGTA alone, there was a significant 75% decrease in collagen activation of p12-LOX. Additional prein-
Incubation with BAPTA/AM virtually abolished 12-H(P)ETE synthesis (Figure 2B). Similarly, a substantial decrease in p12-LOX activity in response to CRP was observed after Ca\(^{2+}\) chelation, although differences were not statistically significant.

Separately, Ca\(^{2+}\) mobilization in response to collagen (10 \(\mu\)g/mL), CRP (10 \(\mu\)g/mL), or thrombin (0.1 U/mL) was determined and compared. It was found that thrombin and CRP caused similar elevations in cytosolic Ca\(^{2+}\), which were approximately two-fold higher than collagen (Figure 2C). Because thrombin is ineffective at stimulating 12-H(P)ETE generation at this concentration, Ca\(^{2+}\) mobilization is required, but not sufficient to stimulate p12-LOX turnover.

**L-655238 Inhibits CRP-Mediated p12-LOX Product Generation**

When incubated with washed platelets, the translocation inhibitor L-655238 (10 \(\mu\)mol/L) significantly inhibited CRP-stimulated 12-H(P)ETE generation (Figure 2D).

---

**Figure 1.** Collagen and CRP stimulate 12-H(P)ETE synthesis in a dose- and time-dependent manner in washed human platelets. A, Generation of 12-H(P)ETE by collagen-activated platelets. \(3 \times 10^8\) platelets in Tyrodes buffer (pH 7.4) and 1 mmol/L CaCl\(_2\) were activated with 10 \(\mu\)g/mL collagen. LOX products were separated on reverse-phase HPLC as described in Materials and Methods. A inset, UV spectrum of platelet-derived 12-H(P)ETE peak showing absorption maximum at 235 nm. B, Generation of 12-H(P)ETE by collagen or CRP-activated platelets. Overlaid chromatograms showing 12-H(P)ETE generation for (i) CRP (10 \(\mu\)g/mL), (ii) collagen (10 \(\mu\)g/mL), and (iii) untreated platelets. C, Dose dependence of collagen activation of p12-LOX. Platelets were incubated with 1 to 10 \(\mu\)g/mL collagen for 10 minutes. D, Time dependence of collagen activation of p12-LOX. Platelets were incubated with 10 \(\mu\)g/mL collagen for 1 to 10 minutes. E, Dose dependence of CRP activation of p12-LOX. Platelets were incubated with 1 to 10 \(\mu\)g/mL CRP for 10 minutes. F, Time dependence of CRP activation of p12-LOX. Platelets were incubated with 10 \(\mu\)g/mL CRP for 1 to 10 minutes.

---

**Figure 2.** Effects of LOX, calcium signaling inhibitors, and a LOX translocation inhibitor on collagen/CRP-mediated p12-LOX activity. All samples were analyzed for 12-H(P)ETE content as described. A, Inhibition of p12-LOX by LOX inhibitors. Platelets were preincubated with the LOX inhibitors baicalein (0.3 \(\mu\)mol/L) or NDGA (60 \(\mu\)mol/L) before adding collagen or CRP. Platelets: a, +collagen; b, +collagen + baicalein; c, +collagen + NDGA; d, +CRP; e, +CRP + baicalein; f, +CRP + NDGA. B, Requirement for calcium signaling in collagen or CRP activation of p12-LOX. Platelets were preincubated with calcium chelators (1 mmol/L EGTA and/or 10 \(\mu\)mol/L BAPTA/AM) before addition of collagen or CRP. Platelets: a, +collagen; b, +collagen + EGTA; c, +collagen + EGTA + BAPTA/AM; d, +CRP; e, +CRP + EGTA; f, +CRP + EGTA + BAPTA/AM. C, Calcium mobilization in response to agonists. Platelets were labeled with FURA-2 as described in Materials and Methods. Background fluorescence ratios were subtracted from all samples. Platelets: a, collagen (10 \(\mu\)g/mL); b, CRP (10 \(\mu\)g/mL); c, thrombin (0.1 U/mL). D, LOX translocation inhibitor, L-655238, inhibits CRP-mediated p12-LOX product generation. Platelets were preincubated with 10 \(\mu\)mol/L L-655238 before adding CRP. Platelets: a, +CRP; b, +CRP + L-655238. *P<0.05 using unpaired t test.

**CRP and Collagen Stimulation of 12-H(P)ETE Generation Requires Signaling by Tyrosine Kinases**

To examine the potential role of tyrosine kinases in p12-LOX activation, staurosporine and the src-family tyrosine kinase inhibitor, PP2, were utilized.\(^{30,31}\) Preincubating platelets with 20 \(\mu\)mol/L staurosporine before collagen or CRP addition caused an approximate 85% inhibition of H(P)ETE genera-
apyrase caused significant inhibition of collagen or CRP-dominethacin (10 nM) had no effect on collagen stimulation, but caused a significant decrease in the CRP response, suggesting that GPVI activation of 12-H(P)ETE generation may involve signaling by p12-LOX. Platelets were preincubated with the PI3-kinase inhibitor wortmannin (100 nM) before the addition of collagen or CRP. Platelets: a, collagen; b, collagen + staurosporine; c, +CRP; d, +CRP + staurosporine. B, Src-family tyrosine kinase inhibition blocks collagen or CRP activation of p12-LOX. Platelets were preincubated with the src-family tyrosine kinase inhibitor, PP2 (50 nM), before adding collagen or CRP. Platelets: a, +collagen; b, +collagen + staurosporine; c, +CRP; d, +CRP + staurosporine. C, p38-MAP kinase inhibition partially blocks CRP-mediated p12-LOX activity. Platelets were preincubated with the p38-MAP kinase inhibitor, SB203580 (10 nM), before adding collagen or CRP. Platelets: a, +collagen; b, +collagen + SB203580; c, +CRP; d, +CRP + SB203580.

Quantification of 12-H(P)ETE Generation by Platelets

<table>
<thead>
<tr>
<th>Treatment</th>
<th>[ng 12-H(P)ETE per 2×10⁶ platelets]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelets only</td>
<td>0.00</td>
</tr>
<tr>
<td>Platelets + collagen (10 μg/mL)</td>
<td>6.50 ± 1.50</td>
</tr>
<tr>
<td>Platelets + CRP (10 μg/mL)</td>
<td>36.01 ± 0.29</td>
</tr>
<tr>
<td>Platelets + thrombin (0.2 U/mL)</td>
<td>0.50 ± 0.70</td>
</tr>
<tr>
<td>Platelets + convulxin (1 μg/mL)</td>
<td>19.50 ± 4.80</td>
</tr>
<tr>
<td>Platelets + A23187 (1 μmol/L)</td>
<td>17.03 ± 0.10</td>
</tr>
<tr>
<td>Platelets + arachidonate (20 μmol/L)</td>
<td>94.80 ± 6.10</td>
</tr>
<tr>
<td>Platelets + U46619 (10 μmol/L)</td>
<td>0.90 ± 0.90</td>
</tr>
<tr>
<td>Platelets + ADP (5 μmol/L)</td>
<td>0.04 ± 0.05</td>
</tr>
</tbody>
</table>

Platelets were preincubated with various agonists before being analyzed by reverse-phase HPLC for 12-H(P)ETE. Data shown are for mean ± SEM, n=3.

PKC Inhibitors Potentiate Agonist-Mediated 12-H(P)ETE Generation

PKC is associated with phosphorylation of cytosolic PLAr and Ca²⁺ mobilization in platelets. Two specific PKC inhibitors, bis-indolylmaleimide and chelerythrine chloride (1 to 10 μmol/L), potentiated collagen and CRP-mediated p12-LOX activity. Also, bis-indolylmaleimide inclusion with U46619, but not ADP, stimulated 12-H(P)ETE synthesis to levels similar to collagen alone (Figure 4C).

Requirement of PGHS-1 or ADP for Collagen and CRP Activation of p12-LOX Product Generation

Although unable to directly activate 12-H(P)ETE synthesis alone (Table), secondary mediators including ADP and U46619, may modulate GPVI-dependent activation. Indomethacin (10 μmol/L) or aspirin (10 mmol/L) were without effect on collagen stimulation, but caused a significant decrease in the CRP response, suggesting that GPVI activation of 12-H(P)ETE generation may involve signaling by p12-LOX (Figure 5A). Preincubation of platelets with 1 U/mL apyrase caused significant inhibition of collagen or CRP-

Figure 3. Tyrosine kinase and PI3-kinase inhibitors block collagen or CRP activation of p12-LOX. A p38-MAP kinase inhibitor partially inhibits CRP-mediated p12-LOX activity. All samples were analyzed for 12-H(P)ETE content as described. A, Staurosporine inhibits collagen or CRP activation of p12-LOX. Platelets were preincubated in the presence of staurosporine (20 μmol/L) before adding collagen or CRP. Platelets: a, +collagen; b, +collagen + staurosporine; c, +CRP; d, +CRP + staurosporine. B, Src-family tyrosine kinase inhibition blocks collagen or CRP activation of p12-LOX. Platelets were preincubated with the src-family tyrosine kinase inhibitor, PP2 (0 to 50 μmol/L), before adding collagen or CRP. Platelets: a, +collagen; b, +collagen + PP2 (5 μmol/L); c, +collagen + PP2 (10 μmol/L); d, +collagen + PP2 (50 μmol/L); e, +CRP; f, +CRP + PP2 (5 μmol/L); g, +CRP + PP2 (10 μmol/L); h, +CRP + PP2 (50 μmol/L). C, p38-MAP kinase inhibition partially blocks CRP-mediated p12-LOX activation. Platelets were preincubated with the p38 MAP kinase inhibitor, MKI (100 nM), before addition of collagen or CRP. Platelets: a, +collagen; b, +collagen + MKI; c, +CRP; d, +CRP + MKI. D, PI3-kinase inhibition blocks collagen or CRP activation of p12-LOX. Platelets were preincubated with the PI3-kinase inhibitor, wortmannin (100 nM), before the addition of collagen or CRP. Platelets: a, +collagen; b, +collagen + wortmannin; c, +CRP; d, +CRP + wortmannin. *P<0.05 using unpaired t test.
stimulated activity (Figure 5B). However inhibition of the collagen response was greater, suggesting ADP signaling may be more important in collagen activation of 12-H(P)ETE synthesis via receptors other than GPVI.

Alterations in 12-H(P)HETE Esterification Do Not Explain Changes in p12-LOX Product Detection

After their generation, H(P)ETEs can be esterified into membrane phospholipids. To examine whether changes in lipid esterification or hydrolysis in the presence of inhibitors could account for the data herein, samples were analyzed for 12-H(P)ETE before and after alkaline hydrolysis. No significant differences were found for controls or samples treated with PP2, wortmannin, bis-indolymaleimide, or aspirin, indicating that 12-H(P)ETE esterification is not taking place during the time course of our assays (data not shown).

**Figure 4.** PKC inhibition potentiates collagen or CRP-mediated p12-LOX product generation, and enhances U46619 (but not ADP)-mediated p12-LOX activity. All samples were analyzed for 12-H(P)ETE content as described. Platelets were preincubated in the presence of PKC inhibitors chelerythrine chloride or bis-indolymaleimide (both 1 to 10 μmol/L) before adding collagen or CRP. A, Collagen activation of p12-LOX is potentiated by PKC inhibition. Platelets: a, +collagen; b, +collagen+chelerythrine (1 μmol/L); c, +collagen+chelerythrine (3 μmol/L); d, +collagen+chelerythrine (10 μmol/L); e, +collagen+bis-indolymaleimide (1 μmol/L); f, +collagen+bis-indolymaleimide (3 μmol/L); g, +collagen+bis-indolymaleimide (10 μmol/L). B, CRP activation of p12-LOX is potentiated by PKC inhibition. Platelets: a, +CRP; b, +CRP+chelerythrine (5 μmol/L); c, +CRP+chelerythrine (10 μmol/L); d, +CRP+bis-indolymaleimide (5 μmol/L); e, +CRP+bis-indolymaleimide (10 μmol/L). C, Bis-indolymaleimide potentiates U46619-mediated (but not ADP-mediated) p12-LOX activity. Platelets: a, +ADP (5 μmol/L); b, +ADP+bis-indolymaleimide (20 μmol/L); c, +U46619 (10 μmol/L); d, +U46619+bis-indolymaleimide (20 μmol/L). *P<0.05 using unpaired t test; for C, % control refers to collagen response.

**Figure 5.** Role of secondary mediators in collagen or CRP stimulation of p12-LOX. All samples were analyzed for 12-H(P)ETE content as described. A, PGHS-1 signaling is involved in CRP but not collagen activation of p12-LOX. Platelets were preincubated with either indomethacin (10 μmol/L) or aspirin (10 mmol/L) before adding collagen or CRP. Platelets: a, +collagen; b, +collagen+indomethacin; c, +collagen+aspirin; d, +CRP; e, +CRP+indomethacin; f, +CRP+aspirin. B, Apyrase inhibits collagen or CRP-mediated p12-LOX activation. Platelets were incubated with the ADP scavenger, apyrase (1 U/mL), before adding collagen or CRP. Platelets: a, +collagen; b, +apyrase+collagen; c, +CRP, d, +apyrase+CRP. *P<0.05 using unpaired t test.

**Discussion**

Using human platelets, a novel receptor-dependent signaling pathway for 12-H(P)ETE synthesis was characterized that utilizes the collagen receptor GPVI. Requirements for GPVI-activation of p12-LOX included src-tyrosine kinases, PI3-kinase, Ca²⁺ mobilization, and p12-LOX translocation, whereas PKC and PECAM-1 were inhibitory.
Coffey et al Platelet 12-Lipoxygenase Activation by GPVI

Collagen or CRP activated 12-H(P)ETE synthesis in a dose- and time-dependent manner (Figure 1), implicating Fcγ chain–coupled GPV1 as a specific p12-LOX–activating pathway in human platelets. Collagen utilizes several cell surface receptors including: GPVI, αβ integrin, GP1b, and bound von Willebrand factor.38,39 However, activation by CRP indicates that GPV1 signaling alone is sufficient to activate p12-LOX. Conversely, thrombin did not activate unless added in amounts far higher than required for platelet aggregation and degranulation. Finally, neither TP receptor signaling nor ADP could activate 12-H(P)ETE generation alone (Table, Figure 5), although U46619 did stimulate in the presence of the PKC inhibitor, bis-indolylmaleimide, suggesting PKC may negatively regulate PGHS-1–dependent activation of p12-LOX activity in platelets (Figure 4C).

GPV1 is a platelet-specific collagen receptor whose importance in vascular collagen signaling is highlighted by observations that sequence dimorphisms are associated with increased risk of myocardial infarction.50,51 GPV1 closely associates with an ITAM present on the Fcγ chain that activates tyrosine kinases via adapter molecules such as SLP-76.32,42–44 Activating GPV1 triggers PI3-kinase turnover, whose products activate phospholipid C2γ (PLCγ2).45,46 PLC forms DAG and IP3, which activate PKC and Ca2+ mobilization, respectively.47,48 GPV1 also causes phosphorylation of p38-MAP kinase, which can directly activate platelet cytosolic PLA2, a potential source of arachidonate substrate for p12-LOX.34,49

To explore requirements for GPV1 activation of p12-LOX, signaling inhibitors were also utilized. Potent inhibition of CRP-mediated 12-H(P)ETE synthesis by BAPTA/AM and EGTA implicated Ca2+ mobilization, which could activate p12-LOX by stimulation of p12-LOX translocation (Figure 2B).30,51 In agreement, a translocation inhibitor, L-655238, substantially inhibited GPV1-dependent 12-H(P)ETE synthesis similar to previous reports using collagen (Figure 2D).15 However, Ca2+ mobilization is not in itself sufficient for p12-LOX activation, because a concentration of thrombin that did not cause 12-H(P)ETE synthesis caused significantly greater Ca2+ mobilization than collagen (Figure 2C).

GPV1 stimulation of 12-H(P)ETE generation was inhibited by PP2, staurosporine, and wortmannin, implicating src-tyrosine kinases and PI3-kinase in p12-LOX activation (Figure 3). Although these pathways are already known to be activated via GPV1, they have not been previously reported to activate H(P)ETE synthesis in mammalian cells, and provide novel insights into intracellular signaling pathways that modulate LOX product formation. In contrast, an inhibitor of p38 MAP kinase (MKI) did not inhibit collagen, and only slightly inhibited CRP-dependent H(P)ETE generation (Figure 3C).

Secondary mediators such as TXA2 and ADP are involved in collagen signaling in platelets and were found to variably regulate collagen or CRP activation of p12-LOX (Figure 5).52 Apyrase significantly inhibited CRP and collagen-mediated 12-H(P)ETE synthesis, but with a greater effect on collagen activation (Figure 5B). Indomethacin or aspirin partially blocked CRP but not collagen-mediated 12-H(P)ETE generation (Figure 5A). Collectively, this indicates that stimulation of H(P)ETE synthesis via GPV1 involves TP signaling, but collagen activation may involve additional receptors signaling independently of the TP receptor and a greater involvement of ADP.38,39

Two PKC inhibitors dose-dependently enhanced collagen/CRP-mediated 12-H(P)ETE synthesis, indicating that PKC negatively regulates GPV1-dependent p12-LOX product generation (Figure 4A). Also, PKC inhibition potentiated U46619 but not ADP stimulation of 12-H(P)ETE generation (Figure 4C). It has been previously shown that PKC is required for U46619 but not ADP-induced platelet activation.53 Inhibition by PKC may involve cross-talk between PKCδ or θ and Bruton’s or Fyn tyrosine kinases in platelets, which was recently described.54–56

In the vasculature, the balance between two distinct signaling motifs, termed ITAM and ITIM, has impact on regulating vascular cell function.52 In platelets, ITAM present on the Fcγ chain coupled to GPV1 is activated through phosphorylation by src-family tyrosine kinases. This is inhibited by proteins possessing ITIM, for example, PECAM-1.58,59 Herein, cross-linking studies utilizing antibodies specific for PECAM-1 demonstrated substantial suppression of GPV1-stimulation of 12-H(P)ETE synthesis. Unexpectedly, isotype controls (omitting anti-PECAM-1 antibodies), showed that cross-linking antibodies alone could potentiate CRP stimulation of 12-H(P)ETE synthesis. Although not understood, this may result from interactions of F(ab′)2, anti-IgG secondary antibody with sites on the platelet surface unrelated to PECAM-1. The observation that cross-linking using specific anti–PECAM-1 antibody markedly inhibits GPV1-mediated 12-H(P)ETE synthesis demonstrates a novel

Downloaded from http://circres.ahajournals.org/ at Cardiff University on February 19, 2014
function for PECAM-1 and a role for ITIM/ITAM-containing immune receptors in modulating 12-H(P)ETE synthesis (Figure 6).

This study presents the first detailed intracellular characterization of a specific receptor-dependent signaling pathway that acutely activates LOX turnover in mammalian cells, and provides a novel link between immune receptor signaling and lipid oxidation in the vasculature.

Acknowledgments

Financial support was from British Heart Foundation (M.I.C., J.M.G., V.B.O.), Wellcome Trust (V.B.O.), and Biotechnology Biological Sciences Research Council (J.M.G.). The authors acknowledge the assistance of Prof S.P. Watson (University of Birmingham, UK) in preparing this manuscript and also Dr P.C. Williams (University of Wales College of Medicine, UK).

References


